ArriVent BioPharma AVBP 深 沪
等待开盘 08-19 09:30:00 美东时间
30.00
+0.990
+3.41%
华盛通- 最 高30.365
- 今 开28.86
- 成交量 40.87万股
- 最 低 28.86
- 昨 收 29.01
- 总市值 14.79亿
- 52周最高 35.83
- 市盈率 静 --
- 换手率 0.83%
- 52周最低 17.00
- 委 比 37.06%
- 总股本 4930.77万
- 历史最高 36.37
- 量 比 0.96
- 振 幅 5.19%
- 历史最低 14.35
- 每 手 1
- 风险率 4.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Veeva Systems To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. raised the price target for Arrivent Biopharma Inc (NASDAQ:AVBP) from $44 to $47. HC Wainw...
08-17 21:01
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
BTIG Reiterates Buy on ArriVent BioPharma, Maintains $42 Price Target
BTIG analyst Jeet Mukherjee reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $42 price target.
08-13 18:14
ArriVent BioPharma Q2 EPS $(1.05) Misses $(0.99) Estimate
ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.99) by 6.06 percent. This is a 16.67 percent decrease over losses of $(0.90) per share from the same period last year.
08-13 04:17
ArriVent BioPharma Reports Second Quarter 2026 Financial Results
ArriVent BioPharma reported second-quarter 2026 financial results with $373.1 million in cash and investments, supporting operations into 2028. Key highlights include advancing firmonertinib for EGFR exon 20 insertion mutant NSCLC with Phase 3 data expected in H2 2026, initiating Phase 1b dose optimization for ARR-217 targeting gastrointestinal cancers, and preparing to dose the first patient with ARR-002 for ovarian and endometrial cancers in Q3...
08-12 20:01
美股大行评级 | Susquehanna上调美光目标价从600美元升至1750美元；戴尔、MongoDB、网泰信息存储、Nextpower、Okta等获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从7美元升至7.5美元；Susquehanna：维持美光科技"积极"评级，目标价从600美元升至1750美元
06-01 14:11
Truist Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $45
Truist Securities analyst Supawat Thongthip maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $43 to $45.
05-30 00:52
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $43
Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $43.
05-14 02:46
ArriVent Biopharma Launches $250M At-The-Market Common Stock Offering Through Jefferies
$250,000,000Common StockWe have entered into an Open Market Sale AgreementSM (the sales agreement) with Jefferies LLC (Jefferies), as our sales agent, relating to the shares of our common stock offered by this prospectus
05-12 04:52
